Ordering
  • Test code: 444743
  • Turnaround time:
    10–21 calendar days (14 days on average)
  • Preferred specimen:
    3mL whole blood in a purple-top EDTA tube (K2EDTA or K3EDTA)
  • Alternate specimens:
    Saliva, assisted saliva, buccal swab and gDNA
  • Sample requirements
  • Request a sample kit
Billing
 

Invitae Prostate Cancer HRR Panel

Test description

The Invitae Prostate Cancer HRR Panel analyzes homologous recombination repair (HRR) genes related to prostate cancer. Analysis of these genes in individuals with an active diagnosis of prostate cancer may assist in identifying potential therapeutic options and inform risks for other cancers. Results of this test may also inform relatives of their cancer risks. Depending on an individual’s clinical and family history, other Invitae hereditary cancer panels may be considered, either as an alternative or in addition to this test.

Order test

Primary panel (10 genes)

ATM BARD1 BRCA1 BRCA2 BRIP1 CHEK2 FANCL PALB2 RAD51C RAD51D

Alternative tests to consider

These genes can also be ordered as part of broader, cross-cancer, multi-gene panels. Depending on the individual’s clinical and family history, one of these broader panels may be appropriate. Any of these broader panels can be ordered at no additional charge.

  • Hereditary breast and ovarian cancer syndrome (HBOC)
  • Ataxia telangiectasia (A-T)
  • Fanconi anemia

To view the complete clinical description of this panel, click here.

The genes on this panel confer an increased risk of developing cancer in an autosomal dominant inheritance pattern. Several also have autosomal recessive inheritance, or result in clinically distinct autosomal recessive conditions.

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below, depending on the specific gene or test. In addition, the analysis covers select non-coding variants. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.

Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
ATM* NM_000051.3
BARD1 NM_000465.3
BRCA1* NM_007294.3
BRCA2* NM_000059.3
BRIP1 NM_032043.2
CHEK2 NM_007194.3
FANCL* NM_018062.3
PALB2 NM_024675.3
RAD51C NM_058216.2
RAD51D NM_002878.3

ATM: Sequencing analysis for exons 6, 24, 43 includes only cds +/- 10 bp.
BRCA1: Sequence analysis includes +/- 20 base pairs of adjacent intronic sequence.
BRCA2: Sequence analysis includes +/- 20 base pairs of adjacent intronic sequence.
FANCL: Sequencing analysis for exons 4, 10 includes only cds +/- 10 bp.